Cooper Companies (NASDAQ:COO) Director Purchases $249,999.18 in Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Paul Keel bought 4,701 shares of the business’s stock in a transaction on Friday, September 11th. The stock was purchased at an average cost of $53.18 per share, for a total transaction of $249,999.18. Following the transaction, the director owned 4,701 shares of the company’s stock, valued at $249,999.18. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Cooper Companies Trading Down 1.5%

COO opened at $53.78 on Friday. The Cooper Companies, Inc. has a 52 week low of $51.01 and a 52 week high of $89.83. The business has a fifty day simple moving average of $70.23 and a 200-day simple moving average of $68.77. The firm has a market cap of $10.23 billion, a P/E ratio of 18.35, a P/E/G ratio of 2.22 and a beta of 0.82. The company has a quick ratio of 0.73, a current ratio of 1.22 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the previous year, the business earned $0.49 EPS. The company’s quarterly revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities analysts expect that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies declared that its board has authorized a stock repurchase plan on Wednesday, September 9th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Institutional Trading of Cooper Companies

A number of large investors have recently made changes to their positions in the company. Algert Global LLC purchased a new position in Cooper Companies in the second quarter valued at approximately $7,655,000. Bank of America Corp DE acquired a new stake in Cooper Companies during the second quarter worth approximately $144,125,000. BlackRock Inc. purchased a new stake in shares of Cooper Companies during the 2nd quarter worth approximately $1,077,762,000. Heartland Advisors Inc. purchased a new stake in shares of Cooper Companies during the 4th quarter worth approximately $15,348,000. Finally, Tocqueville Asset Management L.P. acquired a new position in shares of Cooper Companies in the 2nd quarter valued at $1,502,000. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Cooper Companies News Roundup

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Director Lawrence Kurzius purchased 10,000 shares for approximately $549,300, increasing his position by 47.4%. Other directors, including Paul Keel and Walter Rosebrough Jr., also recently bought shares. The purchases may provide a modest confidence signal from insiders after the selloff. Insider purchase report
• Neutral Sentiment: Jana Partners is pressing Cooper to replace its chief executive and pursue an urgent overhaul, citing “chronic underperformance.” The activist campaign could create a catalyst for strategic change, but it also increases leadership and execution uncertainty. Wall Street Journal activist report
• Negative Sentiment: Cooper’s latest quarterly results beat adjusted EPS expectations, $1.15 versus $1.12, but revenue of approximately $1.07 billion missed the $1.10 billion consensus. Management also reduced fiscal 2026 adjusted EPS guidance to $4.51–$4.55 and revenue guidance to $4.23–$4.25 billion, reflecting weaker contact-lens demand.
• Negative Sentiment: Reports that U.S. distributors are reducing channel inventories have raised concerns about near-term sales and whether the weakness reflects temporary destocking or softer underlying demand. Inventory destocking report
• Negative Sentiment: Pomerantz, Bragar Eagel & Squire, and Levi & Korsinsky announced investigations into potential securities claims. These notices do not establish wrongdoing, but they add legal and headline risk. Analysts have also lowered their consensus price target to about $72.27. Pomerantz investigation

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Zacks Research lowered shares of Cooper Companies from a “hold” rating to a “strong sell” rating in a research note on Friday, September 11th. Citigroup reaffirmed a “neutral” rating and set a $60.00 target price (down from $80.00) on shares of Cooper Companies in a research note on Thursday, September 10th. Bank of America reiterated a “neutral” rating and set a $65.00 target price (down from $80.00) on shares of Cooper Companies in a report on Thursday, September 10th. Wall Street Zen cut shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Saturday, September 12th. Finally, Robert W. Baird set a $61.00 price target on shares of Cooper Companies and gave the stock a “neutral” rating in a research note on Thursday, September 10th. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $71.47.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.